New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Miels will formally assume the role on January 1, 2026
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated
